| Literature DB >> 26906012 |
Yuko Sato1, Yurika Numata-Uematsu1, Mitsugu Uematsu2, Atsuo Kikuchi1, Tojo Nakayama1, Yosuke Kakisaka1, Tomoko Kobayashi1, Naomi Hino-Fukuyo1, Hiroyoshi Suzuki3, Yukitoshi Takahashi4, Yoshiaki Saito5, Naoyuki Tanuma6, Masaharu Hayashi7, Masaki Iwasaki8, Kazuhiro Haginoya9, Shigeo Kure1.
Abstract
Acute encephalitis with refractory, repetitive partial seizures (AERRPS) is characterized by prolonged severe seizures and a high-grade fever. We experienced a boy with severe AERRPS with frequent partial seizures that exhibited right-side predominance. The patient required the continuous intravenous administration of many antiepileptic drugs and respirator management for several months. Methylprednisolone pulse therapy and intravenous immunoglobulin administration were only temporarily effective. The MRI and EEG showed the abnormality in the left occipital lobe. Although occipital lobectomy was performed, his seizures continued. His cerebrospinal fluid exhibited elevated protein and proinflammatory cytokine levels, and was positive for anti-glutamate receptor ε2 antibodies. Pathological examination showed infiltration of many neutrophilic leukocytes, T cells, and microglia in the area exhibiting severe spongiosis. We thought that the exaggerated microglia and T-cell responses were related to the pathogenesis of the patient's seizures, and we therefore initiated treatment with tacrolimus. As a result, many of the daily seizure clusters were ameliorated, and the patient was discharged. We attempted to discontinue the tacrolimus twice, but the patient's seizure clusters recurred each time. This is the first case report of the pathological findings of AERRPS and showing an effective therapeutic approach using tacrolimus. Tacrolimus may be an effective immunosuppressant, especially for patients with severe AERRPS.Entities:
Keywords: Acute encephalitis with refractory; Pathological findings; Repetitive partial seizures (AERRPS); Surgery; Tacrolimus
Mesh:
Substances:
Year: 2016 PMID: 26906012 DOI: 10.1016/j.braindev.2016.02.006
Source DB: PubMed Journal: Brain Dev ISSN: 0387-7604 Impact factor: 1.961